MEIP MEI Pharma
- 3.0500
- -0.0300-0.97%
MEI Pharma News
Express News | Stifel Maintains Hold on MEI Pharma, Maintains $7 Price Target
MEI Pharma Shelves Plans for a Second Return of Capital
Express News | MEI Pharma Inc: Plan Will Reduce Short-Term Expenditures on Me-344 Program
Express News | MEI Pharma Inc: to Prioritize Clinical Development of Voruciclib While Enabling Development of a New Me-344 Formulation for Phase 1 Study
Express News | MEI Pharma Inc - Board of Directors Unanimously Agreed on a Strategic Plan to Leverage Recent Positive Voruciclib and Me-344 Clinical Data
Express News | MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and Me-344
Express News | MEI Pharma Inc - Not to Proceed With Second Capital Return Under 2023 Anson and Cable Car Cooperation Agreement
Express News | MEI Pharma Inc: Me-344 in Combination With Bevacizumab Was Generally Well-Tolerated With No Evidence of Overlapping Toxicity
Express News | MEI Pharma Reports Initial Data From Clinical Study Evaluating Me-344 in Combination With Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients
MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum
MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today announced that David Urso, president and chief executive officer of MEI Pharma, will participate in a fireside chat at the Stifel 2024 Virtual Targeted Oncology Forum on Tuesday, April 16 at 1:30 PM Eastern Time.
Express News | MEI Pharma Announces Enrollment Initiated In 12-Patient Expansion Cohort Evaluating Voruciclib Plus Venetoclax In Ongoing Phase 1 Study; Says Anti-leukemic Activity Across Multiple Heavily Pretreated Patients Demonstrated Along With Anticipated Decreases
Biotech Bankruptcies Hit a Record Despite Sector's Recovery
12 Most Undervalued Biotech Stocks To Buy According To Hedge Funds
MEI Pharma Announces Flexible $25 Million Funding Strategy
MEI Pharma Files for $100M Mixed Shelf
5 Value Stocks In The Healthcare Sector
What is a Value Stock?A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators
MEI Pharma Price Target Cut to $7.00/Share From $8.00 by Stifel
MEI Pharma Price Target Cut to $7.00/Share From $8.00 by Stifel
MEI Pharma Is Maintained at Hold by Stifel
MEI Pharma Is Maintained at Hold by Stifel
MEI Pharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 02/14/2024 54.19% Stifel $8 → $7 Maintains Hold 09/27/2023 98.24% Stifel $10 → $9 Maintains Hold 05/23/202
MEI Pharma Sees Funding Sufficient for at Least Next 12 Months >MEIP
MEI Pharma Sees Funding Sufficient for at Least Next 12 Months >MEIP
Analysis
Price Target
No Data
